An open-label, randomised, parallel-group comparison to investigate the efficacy of Yasmin (30 microg ethinylestradiol, 3mg drospirenone) and Marvelon (30 microg ethinylestradiol, 150 microg desogestrel) on cycle control in healthy Chinese women over 13 cycles
Phase of Trial: Phase III
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary) ; Ethinylestradiol/desogestrel
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer
- 13 Jan 2009 Additional trial identifier 91330 reported by ClinicalTrials.gov.
- 13 Jan 2009 Planned patient number added (842) as reported by ClinicalTrials.gov.
- 13 Jan 2009 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History